mRNA Cancer Trial Halted After Patients DIED Faster on the Shot
BioNTech has terminated a Phase 2 trial of its experimental mRNA cancer shot autogene cevumeran (BNT122) after an independent monitoring board found an imbalance in overall survival, with development partner Genentech confirming there were “more deaths in the vaccine arm.” BioNTech co-developed the Pfizer-BioNTech COVID-19 mRNA vaccine sold as Comirnaty. The cancer jab termination came …
mRNA Cancer Trial Halted After Patients DIED Faster on the Shot Read More »